Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Eric Sanchez is a senior consultant of Integra Continuous Manufacturing Systems with a special focus on the implementation of continuous manufacturing methods. He joined the firm after a successful 31-year career with Janssen Pharmaceuticals.

Fernando J. Muzzio, PhD, is distinguished professor of the School of Engineering at Rutgers, The State University of New Jersey, Piscataway, NJ 08855. Dr. Muzzio is a member of 

 editorial advisory board and President of Integra Continuous Manufacturing Systems.

Articles

Advanced manufacturing technologies are available, but challenges need to be addressed.

 Reshoring Pharmaceutical Manufacturing to the US: Can We Do It?

Sean Milmo is a freelance writer based in Essex, UK.

The EC intends to get tougher on issues such as reliability of drug supplies, particularly essential medicines.

Getting Tough on Supplies

Natalie Balanvosky is just-in-time manufacturing solutions manager, Almac Clinical Services.

Bryan Thompson is production manager, Almac Clinical Services.

Best practices can help ensure supply chain flexibility and viability for biologic drugs in clinical trials.

Demystifying Complex Clinical Trial Kit Preparation

The dispute between the European Commission (EC) of the European Union and pharmaceutical company AstraZeneca continues.



Vaccine Supply Dispute Between EU and AstraZeneca Continues

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Although a necessity, companies must strike a critical balance between protecting innovations with IP and providing affordable access to medicines.

Balancing Innovation Protection and Affordability

Intravacc and Cristal Therapeutics have entered into a strategic collaboration for the development of novel vaccine programs against human diseases.

Intravacc, Cristal Therapeutics Collaborate on Novel Vaccine Platforms

Amid pressure to get more vaccines administered faster, FDA pushes back against changes in dosing regimens.

FDA: Stick with Approved EUAs for COVID-19 Vaccines

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

FDA approval rate speeds up despite COVID-19 complications.

FDA Ends 2020 with High Drug Approval Rate

The right partner can help companies overcome key formulation challenges for biologic drugs.